Future studies should aim to further delineate how MYCN-driven glycosylation patterns interact with the immune microenvironment and explore the therapeutic potential of modulating glycosylation pathways in MYCN-amplified neuroblastoma. This evidence concerns the gene MYCN and neuroblastoma.